Primary Mediastinal Large B-cell Lymphoma Treatment and Prevention of Anthracycline Cardiotoxicity: A Case Report
Center of Haematology named after prof. R.H. Yeolyan, Armenia.
Case Study
World Journal of Advanced Research and Reviews, 2021, 10(01), 132–135
Article DOI: 10.30574/wjarr.2021.10.1.0142
Publication history:
Received on 02 March 2021; revised on 04 April 2021; accepted on 07 April 2021
Abstract:
Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline based chemotherapy improved response rates and survival. Many centers use R-CHOP as standard treatment, but the role of the intensified regimens and consolidation radiotherapy has to be clarified. Recent data coming from retrospective analyses and an ongoing prospective study addressing the problem of consolidation radiotherapy will help to better identify risk groups and apply risk-adapted and effective treatment strategies. The latest research has helped to understand molecular mechanisms of PMBCL pathogenesis and indicated targets of directed therapy for the future.
Keywords:
Primary Mediastinal B-Cell Lymphoma; Anthracycline Cardiotoxicity; Invasive Thymoma; Doxorubicin Cumulative Dose; Mediastinal Mass.
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0